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The Multiple Sulfatase Deficiency Gene
Encodes an Essential and Limiting Factor
for the Activity of Sulfatases
the turnover and degradation of sulfated compounds,
mostly complex molecules that are hydrolyzed in lyso-
somes in concert with acidic glycosidases. Functional
correlation among sulfatases is reflected in a high de-
gree of amino acid sequence similarity along the entire
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active site of alkaline phosphatases (Bond et al., 1997;3 Brunel Institute of Cancer Genetics and
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of the highly conserved cysteine residue localized at thePortland, Oregon 97201
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highly conserved during evolution from bacteria to manSecond University of Naples
(Schmidt et al., 1995; Fey et al., 2001). Bacterial sul-I-80131 Naples
fatases may have either a cysteine or a serine at theirItaly
active site, and both of these are modified to formylgly-
cine, albeit by a different protein machinery (Dierks et
al., 1998; Schirmer and Kolter, 1998).
To date, thirteen sulfatase genes have been identifiedSummary
in humans (Hopwood and Ballabio, 2001; Ferrante et
al., 2002; Morimoto-Tomita et al., 2002). They encodeIn multiple sulfatase deficiency (MSD), a human inher-
enzymes with different substrate specificity and subcel-ited disorder, the activities of all sulfatases are im-
lular localization such as lysosomes, Golgi, and ER (Hop-paired due to a defect in posttranslational modifica-
wood and Ballabio, 2001). Four of these genes, ARSC,tion. Here we report the identification, by functional
ARSD, ARSE, and ARSF, encoding arylsulfatase C, D,complementation using microcell-mediated chromo-
E, and F, respectively, are located within the same chro-some transfer, of a gene that is mutated in MSD and
mosomal region (Xp22.3). They share significant se-is able to rescue the enzymatic deficiency in patients’
quence similarity and a nearly identical genomic organi-cell lines. Functional conservation of this gene was
zation, indicating that they arose from duplicationobserved among distantly related species, suggesting
events that occurred recently during evolution (Francoa critical biological role. Coexpression of SUMF1 with
et al., 1995; Meroni et al., 1996).sulfatases results in a strikingly synergistic increase
The importance of sulfatases in human metabolismof enzymatic activity, indicating that SUMF1 is both
is underscored by the identification of at least eightan essential and a limiting factor for sulfatases. These
human monogenic diseases caused by the deficiencydata have profound implications on the feasibility of
of individual sulfatase activities (Hopwood and Ballabio,enzyme replacement therapy for eight distinct inborn
2001). Most of these conditions are lysosomal storageerrors of metabolism.
disorders in which phenotypic consequences depend
on the type and tissue distribution of the stored material.
Among them are five different types of mucopolysac-Introduction
charidoses (MPS types II, IIIA, IIID, IVA, and VI) due to
deficiencies of sulfatases acting in the catabolism ofSulfatases are hydrolases that cleave sulfate esters from
glycosaminoglycans (Neufeld and Muenzer, 2001) anda wide range of substrates, including glycosaminogly-
metachromatic leukodystrophy (MLD), which is charac-cans, sulfolipids, and steroid sulfates (Parenti et al.,
terized by the storage of sulfolipids in the central and1997; Hopwood and Ballabio, 2001). This protein family
peripheral nervous systems leading to severe and pro-is represented in most eukaryotes and prokaryotes, with
gressive neurologic deterioration (Von Figura et al.,some notable exceptions such as Saccharomices cere-
2001). In addition, two human diseases are caused byvisiae. While in prokaryotes sulfatases are involved in
deficiencies of nonlysosomal sulfatases. These includesulfur scavenging, in vertebrates they are implicated in
X-linked ichthyosis, a skin disorder due to steroid sul-
fatase (STS/ARSC) deficiency (Ballabio and Shapiro,
2001), and chondrodysplasia punctata, a disorder af-*Correspondence: ballabio@tigem.it
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Figure 1. Mapping of the MSD Gene by Microcell-Mediated Chromosome Transfer
(A) Sulfatase activities of clones selected after microcell-mediated chromosome transfer. Each of the 22 autosomes was serially transferred
into the immortalized MSD cell line obtained from case 1 in Table 1. ARSA, ARSB, and ARSC activities were assayed in 25 independent clones
picked after selection with HAT and hygromycin. Average sulfatase activities are expressed in enzymatic units  mg total protein1  3 hr1.
Chromosome 3 clones complement the MSD defect.
(B) Sulfatase activities of individual clones from chromosome 3 transfer. ARSA, ARSB, and ARSC activities of 20 independent clones selected
after chromosome 3 transfer are shown. Results of microsatellite analysis performed on each independent clone are represented with 
and , indicating the presence or absence of the donor chromosome 3, respectively. Wt and / indicate sulfatase activities from control
and MSD cell lines, respectively. Only clones retaining the donor chromosome 3 complement the defect.
(C) Minimal chromosome 3 complementing region. D3S3630 and D3S2397 polymorphic microsatellite markers include the minimal complement-
ing region narrowed after microsatellite analysis performed on clones generated through irradiation microcell-mediated chromosome transfer.
The genes that map within the complementing region are shown.
fecting bone and cartilage due to arylsulfatase E (ARSE) enhancing effect of the SUMF1 gene product on the
activity of sulfatases. The latter finding has direct clinicaldeficiency (Franco et al., 1995). ARSE is also implicated
in a drug-induced human malformation syndrome, War- implications for the therapy of at least eight human dis-
eases caused by sulfatase deficiencies.farin embryopathy, caused by inhibition of the enzymatic
activity due to in utero exposure to warfarin during preg-
nancy (Franco et al., 1995).
In an intriguing human monogenic disorder, multiple Results
sulfatase deficiency (MSD), all sulfatase activities are
simultaneously defective (Austin, 1966; Kolodny and The Gene Mutated in MSD Maps
to Chromosome 3p26Fluharty, 1995; Hopwood and Ballabio, 2001). Conse-
quently, the phenotype of this severe multisystemic dis- To identify the chromosomal location of the gene mu-
tated in MSD, we attempted to rescue the deficient activ-ease combines the features observed in individual sul-
fatase deficiencies. The posttranslational modification ity of sulfatase enzymes by functional complementation
via microcell-mediated chromosome transfer. A panelwhich is required for the activity of all sulfatases was
found to be defective in a cell line from a patient with of human/mouse hybrid cell lines (Cuthbert et al., 1995)
containing individual normal human chromosomesMSD, suggesting that this disorder is caused by a muta-
tion in a gene, or genes, implicated in the cysteine- tagged with the dominant selectable marker HyTK was
used as the source of donor human chromosomes andto-formylglycine conversion machinery (Schmidt et al.,
1995). In spite of an intense biological and medical inter- fused to an immortalized cell line from a patient with
MSD. All 22 human autosomes were transferred one byest, efforts aimed at the identification of the MSD gene(s)
have been hampered by the rarity of MSD patients and one to the patient cell line and hybrids were selected in
hygromycin and HAT-containing medium. Approxi-consequent lack of suitable familial cases to perform
genetic mapping. mately 25 surviving colonies were picked in each of the
22 transfer experiments. These were grown separatelyHere we report the identification of the gene mutated
in MSD by means of functional complementation using and harvested for subsequent enzymatic testing. ARSA,
ARSB, and ARSC activities were tested for each of themicrocell mediated chromosome transfer. Our findings
provide insight into a novel biological mechanism affect- approximately 440 clones (20 22). This analysis clearly
indicated that sulfatase activities of several clones deriv-ing an entire family of proteins in distantly related organ-
isms. In addition to identifying the molecular basis of a ing from the chromosome 3 transfer were significantly
higher compared to those of clones from all other chro-rare genetic disease, our data demonstrate a powerful
SUMF1, a Sulfatase Activator
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Figure 2. Mutations of SUMF1 in MSD Patients
(A) Chromatograms of selected mutations. Case 1: homozygous C  T transition causing a missense mutation; Case 8: heterozygous T  C
transition causing a missense mutation; Case 2: heterozygous deletion of a G causing a frameshift mutation (see Table 1). Arrows indicate
the mutation sites.
(B) Splicing mutations. RT-PCR was performed on the mRNAs from cases 6 and 9. An additional aberrant lower band was detected in both
cases. Sequence analysis showed skipping of exon 3.
(C) Localization of the mutations associated with MSD. SUMF1 exon-intron structure and the locations of all the mutations found are
schematically represented.
mosomes (Figure 1A). However, some of the clones from genotyped using a panel of 31 polymorphic microsatel-
lite markers spanning the entire chromosome. All clonesthe chromosome 3 transfer had low sulfatase activities.
To verify whether each clone had an intact human chro- displaying high enzymatic activities retained chromo-
some 3p26 markers from the donor chromosome. Statis-mosome 3 from the donor cell line, we used a panel of
23 chromosome 3 polymorphic genetic markers that are tical analysis for radiation hybrid mapping was per-
formed as previously described (Boehnke et al., 1991).evenly distributed along the length of the chromosome
and previously selected on the basis of having different Markers D3S1297, D3S1304 and D3S1263 located in
this region showed maximum lod scores of 12.51, 4.76.alleles between donor and patient cell lines. This allowed
us to examine for the presence of the donor chromo- and 9.39 at the estimated distances of 0.30, 0.00, and
0.45 R (rays), respectively. A higher resolution analysissome and to identify possible loss of specific regions
due to incidental chromosomal breakage. As shown in using additional markers from the same region, per-
formed on selected hybrid clones, mapped the putativeFigure 1B, each clone that had high enzymatic activity
retained the entire chromosome 3 from the donor cell line, location for the complementing gene between markers
D3S3630 and D3S2397 (Figure 1C).whereas clones with low activities had lost the entire
chromosome on the basis of the absence of chromo-
some 3 alleles from the donor cell line. The latter clones Identification of the Gene Mutated in MSD
We tested genes from the genomic region shown inprobably retained a small region of the donor chromo-
some containing the selectable marker gene that enabled Figure 1C for mutations in MSD patients. Each exon
including splice junctions was PCR-amplified and ana-them to survive in hygromycin-containing medium. These
data indicate that a normal human chromosome 3 was lyzed by direct sequencing. Mutation analysis was per-
formed on twelve unrelated affected individuals; six pre-able to complement the defect observed in the MSD
patient cell line. viously described MSD patients and six unpublished
cases. Several mutations were identified from our MSDFinally, to determine the specific chromosomal region
containing the gene responsible for the complementing cohort in the anonymous cDNA sequence PSEC0152
(Genbank accession number AK075459), correspondingactivity, we used a Neo-tagged chromosome 3 hybrid,
which often undergoes chromosomal breakage sponta- to a gene of unknown function, strongly suggesting that
this was the gene involved in MSD. Each mutation wasneously (Imreh et al., 1997). In addition, we performed
irradiation microcell-mediated chromosome transfer of found to be absent in 100 control individuals, thus ex-
cluding the presence of sequence polymorphisms. OnHyTK-tagged human chromosomes 3 (Hunt, 1996). One
hundred and fifteen chromosome 3 irradiated hybrids the basis of the functional data reported below and
of previous studies on the biochemical defect in MSDwere tested for ARSA, ARSB, and ARSC activities and
Cell
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Table 1. SUMF1 mutations in MSD patients
Case Phenotype Exon Nucleotide Change Amino Acid Change
1. BA426 moderate 3 463TC S155P
3 463TC S155P
2. BA428 severe neonatal 5 661delG Frameshift
? ? ?
3. BA431 moderate 1 2TG M1R
2 276delC frameshift
4. BA799 mild-moderate 3 463TC S155P
3 463TC S155P
5. BA806 severe neonatal 9 1045CT R349W
9 1045CT R349W
6. BA807 unknown 3 c.5194delGTAA exon 3 skipping
9 1076CA S359X
7. BA809 mild-moderate 1 1AG M1V
9 1042GC A348P
8. BA810 severe 8 1006TC C336R
9 1046GA R349Q
9. BA811 severe neonatal 3 c.5194delGTAA exon 3 skipping
8 979CT R327X
10. BA815 moderate 5 c.603-2delA exon 5 skipping
6 836CT A279V
11. BA919 mild-moderate 9 1033CT R345C
9 1033CT R345C
12. BA920 moderate 5 653GA C218Y
9 1033CT R345C
Cases 1, 2, 3, 4, 6, and 7 were published in Conary et al., 1988; Burch et al., 1986; Zenger et al., 1989; Burk et al., 1981; Schmidt et al., 1995;
and Couchot et al., 1974, respectively. All other cases are unpublished, and their sources are indicated in the Experimental Procedures.
(Schmidt et al., 1995), we designated this gene SUMF1 human chromosome 7q11 that we designated SUMF2
(Genbank accession number NM_015411). SUMF2-(Sulfatase Modifying Factor 1). Sequence chromato-
grams for three different types of mutations are shown encoded protein shares 48% sequence identity and
62% similarity with SUMF1-encoded protein and ap-in Figure 2A. Additional confirmatory mutation analysis
was performed on reverse transcribed patients’ RNAs, pears to be conserved in all vertebrates analyzed, but
absent in more distantly related species.particularly in those cases in which genomic DNA analy-
sis revealed the presence of a mutation in or near a Figure 3A shows the amino acid sequence alignment
of proteins encoded by the SUMF1 gene homologs insplice site, possibly affecting splicing. An example of
such mutation resulting in exon skipping is shown in a selected number of species, including Homo sapiens,
Mus musculus, Fugu rubripes, Drosophila melanogas-Figure 2B. The types and locations of each of the muta-
tions identified are shown in both Figure 2C and Table ter, Anopheles gambiae, and two bacterial species,
Streptomyces coelicolor and Corynebacterium effi-1. In three instances, different patients (case 1 and 4,
case 6 and 9, and case 11 and 12 in Table 1) were found ciens. A high degree of sequence similarity was ob-
served along the entire length of protein sequences,to carry the same mutation. Two of these patients (case
11 and 12) originate from the same town in Sicily, sug- with the exception of the hydrophobic N-terminal region.
The region between the amino acids 303 and 351 of thegesting the presence of a founder effect that was indeed
confirmed by haplotype analysis (data not shown). human SUMF1-encoded protein differs from the corre-
sponding region of SUMF2. Interestingly, this region of
SUMF1-encoded proteins contains three regularlyThe SUMF1 Gene and Protein
The SUMF1 gene contains nine exons and spans ap- spaced cysteine residues which are absent from the
SUMF2-encoded proteins. The spacing of these cys-proximately 106 kb. The consensus SUMF1 cDNA se-
quence (2130 bp), obtained by comparing several cDNA teines is reminiscent of the domain responsible for sul-
fatase modification found in the bacterial sulfur bindingclones with the genomic sequence, is predicted to en-
code a 374 amino acid protein. No previously described proteins. The human SUMF2 sequence appears to be
more similar to the corresponding murine and Fugu ho-domains of known function could be detected in the
coding sequence. A highly hydrophobic region, entirely mologs than to the human SUMF1 sequence, thus sug-
gesting that a second gene was generated early duringencoded by the first exon, was identified at the N termi-
nus, suggesting the presence of a leader peptide possi- vertebrate evolution and evolved independently from
the first gene. This is also evident from the analysis ofbly responsible for proper subcellular localization. Con-
sensus cDNA sequences of SUMF1 gene homologs the phylogenetic tree (Figure 3B).
In silico analysis of ESTs represented in various tis-from other species were also assembled. The predicted
start codon of the human SUMF1 gene is conserved in sues predicts a ubiquitous expression pattern of SUMF1
with a higher abundance in kidney. This was confirmedthe mouse homolog. Sequence comparison also identi-
fied the presence of a SUMF1 gene paralog located on experimentally by Northern blot analysis showing a
SUMF1, a Sulfatase Activator
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Figure 3. SUMF1 Homologs and Evolutionary Conservation
(A) Protein alignment. Shadowed boxes indicate amino acids that are represented in more than 50% of the protein sequences shown. Stars
indicate missense mutations found in SUMF1.
(B) Phylogenetic tree of SUMF1 homologs in selected species. SUMF1 and SUMF2 homologs appear to have evolved independently after
vertebrate speciation.
higher abundance of SUMF1 mRNA in kidney and liver Functional Complementation of Multiple
Sulfatase Deficiencies(Figure 4A). Figure 4B shows the immunofluorescence
analysis of Cos-7 cells transfected with a Myc-tagged Fibroblasts from two MSD patients (case 1 and 12 in
Table 1) in whom we identified mutations of the SUMF1SUMF1 cDNA. Exogenous SUMF1-encoded protein col-
ocalizes with the endoplasmic reticulum marker protein gene (cell lines BA426 and BA920) were infected with
HSV-1 (herpes simplex virus type 1) containing the wild-ERAB.
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Figure 4. SUMF1 Expression and Protein Localization
(A) Northern blot analysis of SUMF1 mRNA. SUMF1 expression was investigated in the indicated tissues. Hybridization of the -ACTIN control
probe is also shown. SUMF1 is expressed ubiquitously with higher levels in kidney and liver.
(B) SUMF1-Myc immunofluorescence analysis. Cos7 cells were transfected with SUMF1-Myc cDNA. Anti-Myc and Anti-ER antibodies were
used for detection. The merged picture demonstrates ER localization of the SUMF1-Myc encoded protein.
type and two mutated forms of SUMF1 cDNA (R327X course study of cells cotransfected with SUMF1 and
ARSA cDNAs, and harvested at 24, 48, and 72 hr afterand ex3). ARSA, ARSB, and ARSC activities were
tested 72 hr after infection. Expression of wild-type transfection, showed a linear increase of ARSA activity
(Figure 5C). Furthermore, cotransfection of increasingSUMF1 cDNA resulted in functional complementation
of all three activities, while mutant SUMF1cDNAs did amounts of SUMF1 cDNA with constant amount of
ARSA cDNA (0.5:1, 0.75:1, 1:1, 1.25:1, 1.75:1, 2.25:1not (Table 2). The disease-associated mutations result
in sulfatase deficiency, thus demonstrating that SUMF1 SUMF1/ARSA ratios) resulted in an increase of ARSA
activity reaching a plateau at high SUMF1/ARSA ratiosis an essential factor for sulfatase activity.
(Figure 5D). Competition of the different sulfatases for
the modification machinery was evident from the obser-SUMF1 Enhancing Effect on Sulfatase Activities
To study the effect of SUMF1 on sulfatase activities, vation that simultaneous overexpression of multiple sul-
fatase cDNAs resulted in a lower increase of each indi-we overexpressed ARSA, ARSC, and ARSE cDNAs in
various cell lines with and without cotransfection of vidual sulfatase activity as compared to the increase
observed when a single sulfatase was overexpressedSUMF1 cDNA and measured sulfatase activities. Over-
expression of sulfatase cDNAs in Cos-7 cells resulted in (Figure 5E).
a moderate increase of sulfatase activity, while a striking
synergistic increase (20- to 50-fold) was observed when Functional Conservation of SUMF1
during Evolutionboth a sulfatase and SUMF1 cDNAs were coexpressed
(Figure 5A). A similar, albeit lower, effect was observed To test for functional conservation of SUMF1 during
evolution, we coexpressed human ARSA, ARSC, andin three additional cell lines, HepG2, HEK293, and U2OS
(Figure 5B). ARSE cDNAs with both the murine and the Drosophila
SUMF1 homologs. Both of them enhanced all three hu-The enhancing effect SUMF1 has on sulfatase activi-
ties was found to be dependent on both time after trans- man sulfatases, with the Drosophila SUMF1 being less
efficient (Figure 5F). These data demonstrate a high de-fection and on the amount of SUMF1 cDNA. A time-
Table 2. Functional Complementation of Sulfatase Deficiencies
Recipient MSD Cell Line Construct ARSA1 ARSB1 ARSC1
BA426 HSV-1 amplicon 24.0 22.5 0.15
SUMF1-ex3 42.0 23.8 0.29
SUMF1-R327X 33.6 24.2 0.16
SUMF1 119.5 (4.9) 37.8 (1.7) 0.62 (4.1)
BA920 HSV-1 amplicon 16.6 11.3 0.15
SUMF1-ex3 17.2 14.4 0.07
SUMF1-R327X 36.0 13.5 0.13
SUMF1 66.5 (4.0) 21.6 (1.9) 0.42 (2.8)
Control range 123.7–394.6 50.6–60.7 1.58–1.80
1 All enzymatic activities are expressed as nmoles 4-methylumbelliferone liberated  mg protein1  3 hrs. MSD cell lines BA426 and BA920
were infected with the HSV-1 amplicon alone, and with constructs carrying either mutant or wild-type SUMF1 cDNAs. The increase of single
arylsulfatase activities in fibroblasts infected with the wild-type SUMF1 gene, as compared to those of cells infected with the vector alone,
is indicated in parentheses. Activities measured in uninfected control fibroblasts are indicated.
SUMF1, a Sulfatase Activator
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Figure 5. SUMF1 Enhances ARSA, ARSC, and ARSE Activities
(A) Cotransfection of SUMF1 with ARSA, ARSC, and ARSE cDNAs in Cos-7 cells. Single transfections were performed with either SUMF1,
ARSA, ARSC, or ARSE cDNAs, or with an empty vector. Double transfections were performed with either SUMF1  ARSA, SUMF1  ARSC,
or SUMF1  ARSE cDNAs at 1:1 ratio. Double transfections showed a 20- to 50-fold increase of enzymatic activities.
(B) Cotransfection of SUMF1 and ARSA cDNAs in different cell lines. HEPG-2, HEK293, and U2OS cell lines were single transfected with either
SUMF1 or ARSA cDNAs. Double transfections were performed with SUMF1  ARSA cDNAs at 1:1 ratio. Increase of ARSA activity was
observed in double compared to single transfections.
(C) Time-course analysis of SUMF1 enhancing effect on sulfatase activities. Cos-7 cells were cotransfected with SUMF1  ARSA cDNAs at
1:1 ratio. Cells were harvested at 24, 48, and 72 hr after transfection. A linear increase of ARSA activity was observed.
(D) Saturation of SUMF1 enhancing effect. ARSA activity was tested after cotransfection of Cos-7 cells with different SUMF1/ARSA ratios. A
plateau of sulfatase activity is reached at high ratios, suggesting that ARSA is completely activated.
(E) Competition among sulfatases for SUMF1 enhancing effect. Cos-7 cells were single transfected with either SUMF1, ARSA, or ARSC cDNAs,
double transfected with either ARSA  ARSC, ARSA  ARSE, ARSC  ARSA, or ARSC  ARSE cDNAs, and triple transfected with ARSA 
ARSC  ARSE cDNAs. The ratio of the cotransfected plasmids was 1:1 and 1:1:1, respectively. Each of the previously described combinations
of plasmids was also cotransfected together with a constant amount of SUMF1 cDNA. Reduced enhancement by SUMF1 of each individual
sulfatase activity in double and triple transfected cells compared to single transfected cells suggests the presence of competition among
sulfatases.
(F) Murine SUMF1, Drosophila SUMF1, and human SUMF2 enhance human sulfatase activities. Cos-7 cells were cotransfected with either
SUMF1  ARSA, mSUMF1  ARSA, dSUMF1  ARSA, or SUMF2  ARSA cDNAs at 1:1 ratio. Cos-7 cells were also single transfected with
ARSA cDNA or with the empty vector. Similarly, cotransfections were performed using either ARSC or ARSE cDNAs instead of ARSA. Enhancing
effects on human ARSA, ARSC, and ARSE enzymatic activities were observed with both the murine and Drosophila SUMF1 genes. A much
lower enhancing effect was also detected with SUMF2.
gree of functional conservation of SUMF1 during evolu- Discussion
tion, suggesting a critical biological importance of its
function. A similar and consistent, albeit much weaker, The study of rare genetic diseases sometimes leads
to the discovery of novel biological mechanisms andeffect was observed by using the SUMF2 gene, sug-
gesting that its protein product also has a sulfatase metabolic pathways. This has been the case for MSD.
The nature of this disorder indicated that all human sul-modifying activity.
Cell
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fatases not only have a related biochemical function, as tients’ DNA. Mutations were found in each patient
tested, strongly suggesting that a single gene is involvedevident from sequence comparison, but also share a
common control of their activity. Somatic cell hybridiza- in MSD. The mutations found were of different types;
the majority (e.g., splice site, start site, nonsense,tion studies between cell lines from patients with single
sulfatase deficiencies and from patients with MSD per- frameshift) putatively result in a loss of function of the
encoded protein, as expected for a recessive disease.formed in the early 1980s showed functional comple-
mentation of the enzymatic deficiency, suggesting that Most missense mutations affect codons corresponding
to amino acids that have been highly conserved duringat least two genes control the function of each sulfatase
protein (Horwitz, 1979; Chang and Davidson, 1980; Bal- evolution, suggesting that these mutations also cause a
loss of function. On the basis of our data, no correlationslabio et al., 1985).
The discovery that sulfatases from a patient with MSD could be drawn between the type of mutation and the
severity of the phenotype; however, more detailed clini-were inactive because they did not undergo the required
posttranslational modification (Schmidt et al., 1995) was cal and biochemical studies are needed in the patients
to address this issue. Many patients were found to bethe first demonstration of a biochemical defect in this
disorder. However, nothing was known about the en- compound heterozygotes, carrying two different muta-
tions. However, a founder effect was identified for onezyme(s) involved in this protein modification machinery
in eukaryotes and, therefore, the molecular basis of MSD mutation originating from a small town in Sicily.
has remained a mystery for many years. The identifica-
tion of a gene responsible for the serine-to-formylglycine SUMF1 Gene Function
modification in bacteria did not aid in finding a human The identity of the SUMF1 gene as the “complementing
functional homolog because of both the different nature factor” was demonstrated by rescuing the enzymatic
of this mechanism (serine versus cysteine) and the large deficiency of three different sulfatases upon expression
evolutionary distance involved (Dierks et al., 1998; of exogenous SUMF1 cDNA, inserted into a viral vector,
Schirmer and Kolter, 1998). in two different patient cell lines. In each case a consis-
Lack of information on the molecular basis of MSD tent, albeit partial, restoration of all sulfatase activities
left several issues unsolved. The defect of sulfatase tested was observed, as compared to control patient
posttranslational modification was detected in a single cell lines transfected with empty vectors. On average,
patient cell line and, since then, the analysis was never the increase of enzyme activities ranged between 1.7-
extended to other patients. Therefore, in principle, the to 4.9-fold and reached approximately half of the levels
biochemical defect could be different between different observed in normal cell lines. Enzyme activity correlated
patients and the lack of locus mapping information left with the number of virus particles used in each experi-
open the possibility of locus heterogeneity, as sug- ment and with the efficiency of the infection as tested by
gested by the presence of a high degree of heterogene- marker protein (GFP) analysis. In the same experiments,
ity of clinical presentation (Kolodny and Fluharty, 1995). vectors containing SUMF1 cDNAs carrying two of the
Furthermore, a residual sulfatase activity, of variable mutations found in the patients, R327X and ex3, were
degree, was observed in all MSD patients studied. This used and no significant increase of enzyme activity was
could be due to hypomorphic (i.e., partial loss of func- observed.
tion) mutations in MSD patients allowing for a residual Our mutational and functional data strongly suggest
function. Alternatively, an additional gene might exist that the SUMF1-encoded protein is responsible for the
which partially compensates for the total loss of function previously described posttranslational modification re-
of the gene involved in MSD. The cloning of SUMF1 quired for sulfatase activity (Schmidt et al., 1995). Re-
has now allowed some of these important issues to be cently, we became aware that another group indepen-
solved. dently discovered the same gene using a biochemical
approach based on an in vitro assay, enabling them
to measure the cysteine to formylglycine modificationMolecular Basis of MSD
Based on the hypothesis that the disease gene should (Dierks et al., 2003, this issue of Cell). On the basis of
our data and of those of the accompanying paper, webe able to complement the enzymatic deficiency in a
patient cell line, we performed microcell-mediated chro- named the protein encoded by SUMF1 formylglycine-
generating enzyme (FGE).mosome transfer to an immortalized cell line from a
patient with MSD. This technique has been successfully The SUMF1 gene shows an extremely high degree
of sequence conservation across all distantly relatedused for the identification of genes whose predicted
function could be assessed in cell lines (e.g., by measur- species analyzed, from bacteria to man. We provide
evidence that the Drosophila homolog of the humaning enzymatic activity or by detecting morphologic fea-
tures). To address the problem of stochastic variability SUMF1 gene is able to activate overexpressed human
sulfatases, proving that the observed degree of se-of enzyme activity, we measured the activities of three
different sulfatases (ARSA, ARSB, and ARSC) in the quence similarity of the SUMF1 genes of distantly re-
lated species correlates with a striking functional con-complementation assay. The results of chromosome
transfer clearly indicated mapping of the complement- servation. A notable exception is yeast, which appears
to lack the SUMF1 gene as well as any sulfatase-encod-ing gene to chromosome 3. Subregional mapping to
chromosome 3p26 was achieved by generating a radia- ing genes, indicating that sulfatase function is not re-
quired by this organism and suggesting the presencetion hybrid panel.
Once the critical genomic region was defined, the of a reciprocal influence on the evolution of SUMF1 and
sulfatase genes.SUMF1 gene was identified by mutation analysis in pa-
SUMF1, a Sulfatase Activator
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FGE, the protein product of the SUMF1 gene, belongs
to a previously identified protein family classified as
“unknown function,” indicating that no known functional
domains could be assigned to any of these proteins in
any species. Interestingly, there are two homologous
genes, SUMF1 and SUMF2, in the genomes of all verte-
brates analyzed, including humans. As evident from the
phylogenetic tree, the SUMF2 gene appears to have
evolved independently from the SUMF1 gene. In our
assays, the SUMF2 gene is also able to activate sul-
fatases; however, it does it in a much less efficient man-
ner compared to the SUMF1 gene. This may account
for the residual sulfatase activity found in MSD patients
and suggests that a complete deficiency of all sulfatases
might be lethal. At the moment we cannot rule out the
possibility that SUMF2 has an additional, yet unknown,
function.
Impact on the Therapy of Diseases Due
to Sulfatase Deficiencies
Figure 6. SUMF1 Is Both an Essential and a Limiting Factor for theA strong increase, up to 50-fold, of sulfatase activities
Activity of Sulfatases
was observed in cells overexpressing SUMF1 cDNA to-
(A) In physiological conditions endogenous SUMF1 is able to acti-
gether with either ARSA, ARSC, or ARSE cDNAs, com- vate all endogenous sulfatases.
pared to cells overexpressing the sulfatases alone. In (B) In MSD, loss of function mutations in SUMF1, represented by a
all cell lines we found a significant synergistic effect, star, result in impaired activation of all sulfatases.
(C) Overexpression of a sulfatase results in an increased amount ofindicating that SUMF1 is a limiting factor for the activity
protein (larger circle) but partial enzymatic activity (smaller circle),of sulfatases. This synergistic effect appears to be time-
resulting from incomplete activation due to limited availability ofdependent and saturable. Simultaneous overexpression
SUMF1-encoded protein.
of several sulfatase genes results in competition for the (D) A complete activation of the sulfatase occurs only when both
modifying function of SUMF1-encoded protein. In addi- a sulfatase and SUMF1 are simultaneously overexpressed (larger
tion, variability was observed among different sul- circles).
fatases, possibly due to different affinity of the SUMF1-
encoded protein for the various sulfatases.
The variability observed between different cell lines are currently being performed for two congenital disor-
ders due to sulfatase deficiencies, MPSII (Hunter syn-may be due to different levels of endogenous SUMF1.
Consistent with these observations, we found that the drome) and MPSVI (Maroteaux-Lamy syndrome), and
will soon be extended to a large number of patients.expression of the SUMF1 gene varies among different
tissues, with significantly higher levels in kidney and Toward the goal of achieving an efficient production of
active sulfatases for enzyme replacement in humans,liver. This may have important medical implications, as
tissues with low SUMF1 gene expression levels may the SUMF1 gene was transiently expressed in two differ-
ent cell lines stably overproducing either iduronate-2-be less capable of effectively modifying overexpressed
sulfatase proteins. It will be important to test whether sulfatase (I2S) or N-acetyl-galactosamine-6-sulfatase
(GALNS), which are the enzymes defective in HunterSUMF1 activity is truly rate limiting in some tissues in
vivo. Together, these data suggest that the function of and Morquio A syndromes, respectively. These cell lines
were developed for mass enzyme production to be usedthe SUMF1 gene has evolved to achieve a dual regula-
tory system, with each sulfatase being controlled by an in enzyme replacement trials (Transkaryotic Therapies,
Inc.). A significant increase of activity was observed forindividual mechanism, responsible for the mRNA levels
of each structural sulfatase gene, and by a common both enzymes, although of a different magnitude: 50-
fold for GALNS and 5-fold for I2S (data not shown).mechanism controlled by the levels of SUMF1. In addi-
tion, SUMF2 provides partial redundancy for sulfatase These experiments were performed as part of a collabo-
rative effort between Dr. Mike Heartlein, Transkaryoticmodification. Figure 6 shows a model to explain SUMF1
enhancing effect on sulfatase activities, underscoring Therapies Inc., Dr. Kurt von Figura’s laboratory, and
our group. Based on these observations, future massthe importance of having sufficient amounts of SUMF1-
encoded protein to reach complete activation of overex- sulfatase production efforts will certainly involve coex-
pression of SUMF1.pressed sulfatases.
These data have profound implications for the effec- We envision that SUMF1 may also be used, synergisti-
cally with single sulfatase genes, in gene therapy effortstiveness of mass production of active sulfatases to be
utilized in enzyme replacement therapy. Enzyme re- for sulfatase deficiencies (Matzner et al., 2000; Consiglio
et al., 2001; Toletta et al., 2001; Matzner et al., 2002; Hoplacement studies have been reported on animal models
of sulfatase deficiencies, such as a feline model of mu- et al., 2002). Along these lines, of particular interest are
the results obtained in a recent study on bone marrowcopolysaccharidosis VI, and proved to be effective in
preventing and reducing several symptoms (Crawley et gene transfer in a mouse with metachromatic leukodys-
trophy (ARSA deficiency) (Matzner et al., 2002). In thisal., 1997; Byers et al., 2000). Therapeutic trials in humans
Cell
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3 fragments. Microcells were produced as described in the sectionstudy, unexpectedly high levels of ARSA were needed
above and irradiated by  irradiation of 5 krad. Irradiated microcellsfor the correction of the metabolic defect. In addition,
were fused with the recipient cell line. Finally, 48–72 after fusion,a low specific activity of the enzyme was reported in at
hygromycin B (400 U/ml) and HAT 1 selection were applied.
least one of the treated mice. Interestingly, the tissue
showing the highest levels of enzyme activity was the Microsatellite Analysis
kidney, which is also the tissue where SUMF1 mRNA Polymorphic microsatellite markers were tested for their ability to
appears to be most abundant. Delivery of SUMF1 simul- differentiate between the endogenous chromosomes and the chro-
mosomes derived from the donor cell lines. 5	 6-FAM modified oligo-taneously with sulfatase genes to animal models of sul-
nucleotides were used to amplify polymorphic microsatellites onfatase deficiencies may result in a more effective treat-
DNA isolated from the clones obtained by microcell-mediated chro-ment by increasing sulfatase activity, particularly in
mosome transfer or irradiation microcell-mediated chromosome
those tissues in which the availability of the SUMF1- transfer. PCR products were resolved after loading on a capillary
encoded protein is a limiting factor. column.
Experimental Procedures
Amplicon Production and Infection
The MSD cell lines from case 1 and case 12 were infected withConstructs and Cell Lines
HSV-1 amplicons expressing SUMF1 cDNA, and the mutated formsSUMF1, SUMF2, mSUMF1, and dSUMF1 cDNAs were amplified by
979CT and c.5194delGTAA. Amplicon production and infectionRT-PCR and cloned in pCDNA3 vector. A Myc tag was cloned at
were performed as previously described (Wade-Martins et al., 2001).the 5	 end of the SUMF1 cDNA in the pCDNA3 vector. SUMF1 cDNA,
979CT, and c.5194delGTAA mutants were cloned in pHGCX
Transient Transfection(Saeki et al., 2001). ARSC and ARSE cDNAs were available in our
Cos-7, HEPG-2, HEK293, and U2OS cell lines were transiently trans-laboratory (Franco et al., 1995). ARSA cDNA was previously de-
fected with FuGENE 6 reagent according to the manufacturer’s in-scribed (Stein et al., 1989) and kindly provided by A. Consiglio, Dibit,
structions (ROCHE).San Raffaele Hospital, Milan, Italy.
The MSD fibroblast cell lines reported are the following:
Case 1, BA426 GM3245 (Coriell Cell Repositories). BA426 was Sulfatase Enzymatic Analysis
immortalized by transfection of a construct containing SV40 small Cells were harvested 48–72 hr after infection or transfection, washed
t antigen and an expression construct for the catalytic subunit of with PBS, and disrupted by 3 cycles of freezing-thawing. Likewise,
human telomerase. Case 2, BA428 G1022/94 provided by A.H. Fen- independent clones selected after MMCT or XMMCT were grown,
som, Guy’s Hospital, London, UK. Case 3, BA431 GM12659 (Coriell washed with PBS, and disrupted by 3 cycles of freezing-thawing.
Cell Repositories). Case 4, BA799 GM04681 (Coriell Cell Repositor- Protein concentration was measured in total homogenates. For all
ies). Case 5, BA806 G1608/97 provided by A. Kohlschu¨tter, Ham- enzyme activity assays, 20–30 
g of proteins were incubated at
burg, Germany. Case 6, BA807 and Case 7, BA809 provided by J. 37C for 3 hr under the specific assay conditions.
Couchot, Clinic de Pediatrie et Puericulture, Reims, France. Case For ARSA assay, homogenates were incubated with 0.05 M
8, BA810 G1480/96 provided by E. Zammarchi, Department of Pedi- p-nitrocatechol sulfate in 0.25 M acetate buffer (pH 5) containing
atrics, University of Florence, Italy. Case 9, BA811 G2134/99 pro- 0.85 M NaCl and 0.25 mM Na pyrophosphate in an incubation volume
vided by M. Beck, Mainz, Germany. Case 10, BA815 provided by of 0.3 ml. The reaction was stopped with 0.7 ml 0.64 N NaOH and
R. Carrozzo, Milan, Italy. Case 11, BA919 and Case 12, BA920 pro- absorbance was read at 515 nm on a Perkin Elmer spectropho-
vided by M. Filocamo, Gaslini Hospital and Telethon Cell Line and tometer.
DNA Bank, Genoa, Italy. For ARSB, ARSC, and ARSE enzymatic activity 4-methylumbelli-
feryl (4-MU) sulfate was used as substrate. ARSB activity was deter-
Microcell-Mediated Chromosome Transfer (MMCT) mined by incubating cell homogenates with 6.25 mM 4-MU sulfate
A panel of human:mouse monochromosomal hybrids was used as in 0.375 mM AgNO3 0.1 M NaOAc buffer (pH 5) in 80 
l of incubation
source of normal human donor chromosomes (Cuthbert et al., 1995). mixture. ARSC was measured by incubating cell homogenates with
All 22 autosomes were serially transferred into the immortalized 0.2 mM 4-MU sulfate in 0.25% Triton X100, 0.05 M phosphate buffer
BA426 MSD cell line by microcell-mediated chromosome transfer. (pH 8) in 0.2 ml incubation volume. ARSE was assayed by incubating
Briefly, the donor cells were plated on plastic bullets in DMEM cell homogenates with 0.2 mM 4-methylumbelliferyl sulfate in 0.5%
containing 10% fetal bovine serum and hygromycin B (400 U; Calbio- Triton X-100, 75 mM NaCl, 0.05 mM Tris-HCl buffer (pH 7.5) in 0.2
chem). After 24 hr, colcemid solution was added at 0.05 
g/ml final ml incubation volume.
concentration. Micronucleation was allowed to occur for 48 hr. The For ARSB, ARSC, and ARSE assays, the reactions were stopped
micronucleated cells were then washed with PBS, incubated for 30 with 2 ml glycine-carbonate buffer pH (10.7) and fluorescence was
min at 37C in DMEM without serum containing 10 
g/ml Cytocha- read at 365 nm (excitation) and 450 nm (emission) on a Turner
lasin B, and centrifuged in the same medium in a prewarmed centri- fluorometer.
fuge at 34C for 30 min at 15,000 rpm. The crude microcell pellet
was resuspended in serum-free MEM medium and filtered through
Northern Blot Analysis8 
m and 5 
m filters. The purified microcells were spun at 2000
A membrane carrying a panel of human polyA RNA was hybridizedrpm for 10 min and resuspended in serum-free MEM medium. The
with 32P-labeled SUMF1 and -ACTIN probes according to the man-microcell suspension was added to the plate containing the recipient
ufacturers instructions (Clontech).cells along with phytohemoagglutinin P at 200
g/ml final concentra-
tion and incubated for 15 min at 37C. Microcells were fused with
Immunofluorescence Staining50% PEG for 55 s, washed three times with serum-free MEM me-
Cos-7 cells seeded on Lab-Tek Chamber Slide (Nalge Nunc Interna-dium, and incubated in 15% FCS MEM medium. After 48–72 hr,
tional) were transfected with SUMF1-Myc cDNA. Forty-eight hoursthe fused cells were selected in hygromycin B (400 U/ml) and HAT
after transfection, cells were fixed with 100% methanol for 5 min at1. MMCT was performed as described above using the Neo-
20C, permeabilized with 0.2% Triton X-100 in phosphate-bufferedtagged human:mouse chromosome 3 hybrid GM11713 (Coriell Cell
saline for 15 min at room temperature, and processed for immunoflu-Repositories) as donor cell line. Selection was performed with G418
orescence staining. Cells were incubated with mouse anti-Myc poly-(300
g/ml) and HAT1.
clonal serum 9E10 and with goat polyclonal ERAB (K-20) antibody
(Santa Cruz) for 2 hr at room temperature. The cells were thenIrradiation Microcell-Mediated Chromosome
washed, and incubated with FITC conjugated rabbit anti-mouseTransfer (XMMCT)
Immunoglobulins (DAKO) and with TRITC conjugated donkey anti-A human:mouse monochromosomal hybrid containing human chro-
mosome 3 (Cuthbert et al., 1995) was used as source of chromosome goat immunoglobulin G (Jackson Immuno Research) for 1 hr at room
SUMF1, a Sulfatase Activator
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temperature. Nuclei were stained with Hoechst solution. Pictures M. (1974). Mucosulfatidosis. Study of 3 familial cases. Arch. Fr.
Pediatr. 31, 775–795.were taken with a 63 magnification objective.
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